Nanosuspension: A Review

Abstract

Solubility is the significant component for medication adequacy, freedom of the course of administration Gigantic proportions of recently discovered medications are water insoluble, and hence poorly bioavailable adding to forsook improvement effort. These so‐known as Brickellia' competitors can now be conveyed through detailing them into Nanosuspension. Nanosuspension technological know-how solved the drawback of medications which are inadequately watery dissolvable and less bioavailability. Steadiness and bioavailability of the medications can be expanded by means of the Nanosuspension technology. Coaching of Nanosuspension is simple and relevant to all medicinal drugs which are fluid insoluble. Nanosuspensions are readied through utilizing wet mill, high strain homogenizer, emulsion‐solvent evaporation, melt emulsification approach and super significant fluid systems. Nanosuspension can be prepared with the aid of using stabilizers, natural and organic solvents and different components such as buffers, salts, polyols, osmogent and cry protectant. Nanosuspensions can likewise be delivered with the aid of oral, parenteral, aspiratory and visual courses. Nanosuspensions can additionally be used for distinct drug supply when included in the ocular inserts and mucoadhesive hydrogels.

Keywords

Nanosuspension, Lipid solubility, Particle size, Oral bioavailability

Introduction

Various method parameters that play a relevant position within the successful formulation of medications are aqueous solubility, steadiness at ambient temperature and dampness, photo stability, similarity with dissolvable and excipient. Amongst this watery dissolvability grew to become a hurdle for the system of recent molecular entities. Greater than 40% of the new synthetic substances being produced by means of medication revelation projects are ineffectively water‐soluble or lipophilic mixes. Defining an ineffectively water solvent medication has perpetually been challenging challenge confronted by using the pharmaceutical scientist. The formula of Nano‐sized particles can be applied to all drug compounds belonging to biopharmaceutical classification system (BCS) courses II and IV to build their dissolvability and henceforth parcel into gastrointestinal hindrance. Micronization is utilized for class II medicinal drugs of (BCS), i.e. Medicinal drugs having a excellent permeability and poor solubility. There are a lot of customary methodologies for growing the solvency of inadequately solvent medicines, which comprise micronization, solubilisation using co‐solvents, salt kind, surfactant dispersions, precipitation system, and oily solution. Different approaches are like liposomes, emulsions, micro emulsion, strong dispersion and inclusion complexation using cyclodextrins [1] show intelligent achiever, and however .they need in all inclusive relevance to all medicinal drugs. These methods are now not relevant for those medications which are usually not soluble in aqueous and organic solvents. Nanotechnology can be utilized to remedy the problems associated with these traditional strategies for dissolvability and bioavailability upgrade. Nanosuspension is favoured for intensifies that are insoluble in water (yet are solvent in oil) with high log P cost, unnecessary softening point and high dosages [2-4]. Nanosuspension science will also be used for medications which are insoluble in both water and healthy solvents. There are drug candidates that have bad solubility in water however can be dissolved by compatible conventional formula procedures which incorporate co-solvents, milling methods, super principal processing and stable scatterings including complication and precipitation tactics. Atorvastatin is presently used as calcium salt for the healing of hypercholesterolemia [4-5]. It is insoluble in fluid answer of pH four and beneath; it is very quiet soluble in water and pH 7. Four phosphate buffer. The intestinal penetrability of atorvastatin is excessive at the physiologically crucial intestinal pH. The drug is absorbed extra within the upper duodenum and in the upper little guts areas. Nonetheless, it is stated that absolutely the bioavailability (F) of atorvastatin is 12% after a forty mg oral dose [5-6]. In the reward learn, a strive was once made to the dissolvability and dissolution traits of an ineffectively solvent model medication, atorvastatin calcium (AC) utilising Nanosuspension technological know-how.

Advantages of Nanosuspension[6-8]

Enhance the solubility and bioavailability of medications

Suitable for hydrophilic medications

Larger drug loading can also be done

Dose reduction is feasible

Enhance the bodily and chemical balance of medications

Provides a passive drug concentrating on

When to go for Nanosuspensions Approach

There are two approaches for guidance of Nanosuspension. They're

1. Bottom Up Technology

The time period “Bottom up technology” way that one begins from the molecular degree, and goes by way of molecular organization to the arrangement of a strong molecule. That we are talking about established precipitation approaches by lowering the solvent excellent, for illustration, by means of pouring the solvent right into a nonsolvent or altering the temperature or a combo of each. Precipitation is a classical process in pharmaceutical chemistry and technology [8-10].

Advantages

1. Use of easy and low cost apparatus and

2. Bigger saturation solubility is the advantage for precipitation manner in comparison to different methods of Nanosuspension guidance.Risks [10-12]

Disadvantages [10-14]

1. Precipitation system is no more material to medications which are inadequately solvent in fluid and non-watery media. In this system,the medication goals to be dissolvable in atleast one dissolvable which is miscible with nonsolvent.

2.Prevent crystal progress due to Ostwald ripening being brought about via unique saturation solubilities in the vicinity of otherwise sized particles.

2. Top Down Technology [13-17]

The top down technologies include

(a) Media milling

(b) High pressure homogenization

(c) Emulsion diffusion method

(d) Melt emulsification method

(a) Media milling: Liversidge et al. had a patent on Nano crystal technological know-how. On this technique, medicines are subjected to media processing for nanoparticle generation. Impact of impaction between the processing media and medications gives fundamental vigour for disintegration of the microparticulate method into nanoparticles. On this system, .the council of processing is accused of the processing media including medication, stabilizer, and water or compatible buffer, which is turned around at an awfully high shear cost to produce suspension. Deposits deserted in the completed item are a principal situation of this approach [17-20].

b) High pressure homogenization: This method involve the next three steps: First, tranquilize powders are scattered in a stabilizer solution to kind pre suspension; after that, pre suspension is homogenized with the aid of high strain homogenizer at a low stress in many instances for pre milling; and subsequently homogenized at an excessive pressure for 10 to 25 cycles unless the Nanosuspensions are formed with preferred measurement [20-22].

(c) Emulsion diffusion method: Apart from the usage of emulsion as drug offering auto they can likewise be utilized as formats to provide Nanosuspension. The utilization of emulsions as layouts is material for those medications which might be .dissolvable in both volatile natural solvent and incompletely water‐miscible dissolvable. Such solvents can be utilized in light of the fact that the scattered period of the emulsion. A natural dissolvable or mix of solvents stacked with the medication is scattered in the watery fragment containing reasonable surfactants with blending to type an emulsion. The received emulsion was additional homogenized through excessive strain homogenization. .After homogenization cycles the emulsion used to be weakened with water, homogenized by method for homogenizer to diffuse the characteristic and natural dissolvable also, change over the beads into strong particles. Since one molecule is shaped in every single emulsion bead, it is conceivable to manage the particle measurement of the Nanosuspension through controlling the size of the emulsion [22-24]. Optimizing the surfactant composition increases the intake of organic phase and finally the drug loading within the emulsion. In the beginning methanol, ethanol, ethyl acetate, and chloroform are used as healthy solvents. However, environmental dangers and human security concerns about residual solvents have confined their use in hobbies manufacturing approaches. Nanosuspension of ibuprofen46, diclofenac, and acyclovir had been prepared via this process.

d) Melt emulsification method: In this procedure medication is scattered in the watery arrangement of stabilizer and warmed over the liquefying variable of the medication and homogenized to give an emulsion. During this strategy, the example holder was enwrapped with a warming tape outfitted with temperature controller and the temperature of emulsion used to be kept up over the dissolving component of the medication. The emulsion was then chilled off either gradually to room temperature or on an ice‐tub [24-25].

Advantages

Soften emulsification system relative to the solvent diffusion system is complete avoidance of organic solvents throughout the production procedure.Eg. Nanosuspension of ibuprofen was all set through this system. Formulating ibuprofen Nanosuspension by soften emulsification approach exhibit higher dissolution fee than formulating by way of solvent diffusion approach [25-26].

Pharmaceutical Application Of Nanosuspension [27-30]

By means of making use of postproduction handling, Nanosuspensions are set up into different dose types. Nanosuspension raises dissolution rate and absorption of drug because of smaller particle dimension and bigger surface field [30-35]. By way of utilizing postproduction processing, Nanosuspensions are all set into various dosage types. Nanosuspension raises dissolution expense and absorption of drug as a result of smaller particle measurement and larger floor subject.

Oral Drug Delivery [36-39]

Negative solubility, incomplete solvency, deficient disintegration, and inadequate adequacy are the fundamental obstacle of oral medication organization. As an aftereffect of smaller particle dimension and far larger floor to volume ratio, oral Nanosuspensions are exceptionally used to develop the absorption price and bioavailability of ineffectively dissolvable medications [40] if there should arise an occurrence of azithromycin Nanosuspensions, more than sixty five% drug was observed to be broken down in 5 hours as when contrasted and 20% of micronized medicines [41]. The Nanosuspension have focal points like increased oral assimilation, measurements proportionality, and low intersubject variability. Via using typical fabricating strategies, drug Nanosuspensions will also be easily included into more than a few dosage forms like drugs, capsules, and rapid melts. The Nanosuspension of Ketoprofen used to be efficiently included .into pellets for the maintained unencumber of drug over the period of 24 hours.

Parental Drug Delivery

The reward systems for parental delivery comprise micellar options, salt formation, solubilization using cosolvents, cyclodextrin complexation, and extra recently vesicular programs akin to liposomes and niosomes. However these methods have barriers like solubilization ability, parental acceptability, high manufacturing fee, and so on. To resolve the above issues, the Nanosuspension science is used. Nanosuspensions are regulated through different parental courses comparable to intraarticular, intraperitoneal, intravenous, and many others. Additionally, Nanosuspensions expand the adequacy of parenterally managed medicinal drugs. Paclitaxel Nanosuspension was said to have their prevalence in decreasing the median tumor burden [43] Clofazimine Nanosuspension showed an development in balance as good as efficacy above the liposomal clofazimine in Mycobacterium aviumcontaminated feminine mice [44-50] Rainbow et al. Showed that intravenous Nanosuspension of itraconazole improved viability of antifungal undertaking in rats relative to the answer formulation [51-55].

Pulmonary Drug Supply

For pulmonary delivery, Nanosuspensions may also be nebulized by means of mechanical or ultrasonic nebulizers. Due to the nearness of numerous little particles all vaporized beads incorporate drug nanoparticles. Budesonide corticosteroid has been effectively prepared within the form of Nanosuspension for pulmonary supply [55-66] Aqueous suspensions of the drug can also be quite simply nebulized and given by way of pulmonary route because the particle dimension may be very small. Extraordinary forms of nebulizers are to be had for the administration of liquid formulations. One of the medications effectively tried with pulmonary route are budesonide, ketotifen, ibuprofen, indomethacin, nifedipine, itraconazole, interleukin-2, p53 gene, leuprolide, doxorubicin, etc [67-73].

Ocular Drug Supply [74-77]

Nanosuspensions are utilized as a part of visual conveyance of the medications for supported free up. Liang and associates arranged cloricromene Nanosuspension for visual supply using Eudragit. Check affirmed better accessibility of medication in fluid humor of rabbit eye. Accordingly, Nanosuspension components offer a promising method of bettering the shelf-existence and bioavailability of drug after ophthalmic software [78].

Distinct Drug Delivery

Nanosuspensions are compatible for targeting precise organs considering that of their surface houses. Along with this, it is anything but difficult to modify in vivo conduct by altering the stabilizer [79-86]. The drug will probably be taken up by the mononuclear phagocytic method which allows area-particular delivery. This can be utilized for focusing on antifungal, antimycobacterial, or antileishmanial pharmaceuticals to macrophages if the pathogens continue intracellularly [87-92] Kayser formulated an aphidicolin Nanosuspension that extended the drug concentrating on to macrophages that have been Leishmania infected. He acknowledged that the drug within the type of Nanosuspension had EC50 of zero.003 μg/ml, whereas the traditional form had 0.Sixteen μg/ml. Scholer et al. Described an superior drug concentrating on to brain within the treatment of toxoplasmic encephalitis making use of an atovaquone Nanosuspension [93-100].

Conclusion

Nanosuspensions are exceptional and commercially viable technique to remedy … the issues of hydrophobic medication. Akin to terrible solvency and poor bioavailability. For gigantic-scale construction of Nanosuspensions, media processing and high-weight homogenization science had been efficaciously used. Placing traits, like development of dissolution velocity, expanded saturation solubility, accelerated bioadhesivity, flexibility in surface change, and simplicity of postproduction preparing, have enlarged the utilizations of Nanosuspensions for quite a lot courses of organization. The utilizations of Nanosuspensions in oral and parental courses have been extremely good headquartered, despite the fact that purposes in pneumonic and visual conveyance must be assessed. However, their supply by means of buccal, nasal, and topical delivery is but to be accomplished.

References

1. Reure J, et al. Her2 Positive Metastatic Breast Cancer Patient without Any Sign of Recurrence 5 years after Cessation of Trastuzumab: A Case Report Clin Pharmacol Biopharm. 2015;4:136.
2. Morin C, et al. Late Onset Infections after Surgical Treatment of Spinal Deformities in Children. J Spine. 2015;4:262.
3. Bhat IH, et al. Clinical Profile and Outcome in Distal Gastrointestinal Tract Obstruction in Neonates with Special Emphasis on Role of Colostomy and its Complications. Anat Physiol. 2016;6:222.
4. Abbas A. Screening and Prevention of Transmission of HIV-1 in Neonates Born to Mothers with HIV. Int J Pub Health Safe. 2016; 1:103.
5. Saito M, et al. High Dose Octreotide for the Treatment of Chylothorax in Three Neonates. J Neonatal Biol. 2016;5:218.
6. Ogbalu OK, et al. A New Trend of Omphalitis Complicated with Myiasis in Neonates of the Niger Delta, Nigeria. Epidemiology Sunnyvale. 2016;6:231.
7. Kurt A, et al. Exposure to Environmental Tobacco Smoke during Pregnancy Restrain the Antioxidant Response of their Neonates. J Neonatal Biol. 2016;5:210.
8. Kondo M.NPC-11 Phase III Trial Concerning Apnea of Prematurity in Japanese Neonates: A Study of Safety, Efficacy and Pharmacokinetics. Pharm Anal Acta. 2016;7:458.
9. Garcia AJ and Smith JM Bile Duct Brushings in a Jaundiced Woman. 2015.
10. Alvarez AM, et al. Non-communicating Mucinous Biliary Cystadenoma as a Rare Cause of Jaundice. J Cytol Histol. 2015; 6:369.
11. Morin C, et al. Late Onset Infections after Surgical Treatment of Spinal Deformities in Children. J Spine. 2015; 4:262.
12. Bhat IH, et al. Clinical Profile and Outcome in Distal Gastrointestinal Tract Obstruction in Neonates with Special Emphasis on Role of Colostomy and its Complications. Anat Physiol. 2016;6:222.
13. Abbas A. Screening and Prevention of Transmission of HIV-1 in Neonates Born to Mothers with HIV. Int J Pub Health Safe. 2016;1:103.
14. Susanne B, et al. In vitro and in vivo evaluation of a new sublingual tablet system for rapid Oro mucosal absorption using fentanyl citrate as the active substance. European J Pharm Sc. 2003;20:327-334.
15. Nibha KP and Pancholi SS. An Overview on: Sublingual Route for Systemic Drug Delivery. Int J Res Pharm Biomed Sc. 2012;3:913-923.
16. Saito M, et al. High Dose Octreotide for the Treatment of Chylothorax in Three Neonates. J Neonatal Biol. 2016;5:218.
17. Strehlow B, Bakowsky U, Pinnapireddy SR, Kusterer J, Mielke G, et al. A Novel Microparticulate Formulation with AllicinIn Situ Synthesis. J Pharm Drug Deliv Res. 2016;5:1.
18. Lee S, et al. Lifetime Assessment of POCT Strips through Accelerated Degradation Test. Pharm Anal Acta. 2016; 7:475.
19. Abdou EM and Ahmed NM. TerconazoleProniosomal Gels: Effect of Different Formulation Factors, Physicochemical and Microbiological Evaluation. J Pharm Drug Deliv Res. 2016;5:1.
20. Adesina SK, et al. Nanoparticle Characteristics Affecting Efficacy. J Pharm Drug Deliv Res. 2016;5:1.
21. Parteni O, et al. The Release of Tacrolimus from a Cotton Biomaterial to Dermis. J Pharm Drug Deliv Res 2016;5:1.
22. Ogbalu OK, et al. A New Trend of Omphalitis Complicated with Myiasis in Neonates of the Niger Delta, Nigeria. Epidemiology Sunnyvale. 2016;6:231.
23. Per mender R, et al. Novel Statistically Designed Qbd Methodology for Quantitative Analysis of Nisoldipine in Pharmaceutical Dosage Forms. Pharm Anal Acta. 2016;7:489.
24. Fender P, et al. Adenovirus dodecahedron, a new vector for human gene transfer, Nat Biotechnol.(1997);15:52-6.
25. Garcel A, et al.Protein transduction into human cells by adenovirus dodecahedron using WW domains as universal adaptors, J Gene Med.(2006);8:524-31.
26. Zochowska M, et al. Adenovirus dodecahedron, as a drug delivery vector,PLoS One.(2009);l4:e5569.
27. Szurgot I, et al. Self-adjuvanting influenza candidate vaccine presenting epitopes for cell-mediated immunity on a proteinaceous multivalent nanoplatform, Vaccine.(2013);31:4338-46.
28. Sebestik J, et al. applications, Amino Acids.(2011);40:301-70.
29. Adenovirus dodecahedron, a new vector for human gene transfer,van den Berg A andDowdy SF. Protein transduction domain delivery of therapeutic macromolecules,CurrOpinBiotechnol.(2011);22:888-93.
30. Sumida SM, et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein, J Immunol.(2005);174:7179–85.
31. Fuschiotti P, et al.Structure of the dodecahedral penton particle from human adenovirus type 3, J Mol Biol.(2006);356:510-20.
32. Sonenberg N andGingras AC. (1998) The mRNA 5' cap-binding protein eIF4E and control of cell growth,CurrOpin Cell Biol.(1998);10:268-75.
33. Protein transduction into human cells by adenovirus dodecahedron using WW domains as universal adaptors,
34. Lejbkowicz F, et al. A fraction of the mRNA 5' cap-binding protein, eukaryotic initiation factor 4E, localizes to the nucleus,ProcNatlAcadSci U S A.(1992);89:9612-6.
35. Adenovirus dodecahedron, as a drug delivery vector,
36. Kowalska J, et al. Phosphorothioate analogs of m7GTP are enzymatically stable inhibitors of cap-dependent translation,Bioorg Med ChemLett.(2009);19:1921-5.
37. Zochowska M, et al. Virus-like particle-mediated intracellular delivery of mRNA cap analog with in vivo activity against hepatocellular carcinoma,Nanomedicine.(2015);11:67-76.
38. Malika Vet al. Nano-Carrier for accentuated transdermaldrug delivery. J Develop Drugs. 2014;3:121.
39. Gestal MC and Escalante S. New initiative in ecuador, the creation of a national reference laboratory for antibiotic resistance. J Develop Drugs. 2014;3:122.
40. Sarkar Set al. Differential electrostatic interactions between granular species in a simple hopper chute geometry. J Develop Drugs. 2014;3:123.
41. Joachim Mülleret al. Escherichia coli are susceptible to thiazolides if the tolc efflux system is inhibited. J Develop Drugs. 2014;3:124.
42. Matsumoto Set al. Invitro synergistic effects of anthracycline antitumor agents and fluconazole against azole-resistant candida albicans clinical isolates. J Develop Drugs. 2014;3:125.
43. Carvalho LPet al. Anti-Parasite effects of new thiosemicarbazones and their products thiazolidinone including cellular aspects of intracellular elimination of trypanosoma cruzi in vitro. J Develop Drugs. 2014;3:126.
44. Kanwar SSet al. Personalized medicine through circulating tumor cells: the new dimension in cancer research. J Develop Drugs. 2013;2:e128
45. Vaidya A. Drug designing and development: emerging role of health technology assessment. Drug Des. 2014;3:111.
46. Chow SC and Pong A. Statistical designs for pharmaceutical/clinical development. Drug Des. 2014;3:112.
47. JokanovicV. The deep scientific and philosophic approach to the future nanomedicine, given on the base of author
48. introduction  in  the  monograph  “nanomedicine,  the  greatest  challenge  of  the  21st  century”.  Drug Des.2014;3:113.
49. Gomase VS and Chitlange NR. Sensitive quantitative predictions of mhc binding peptides and fragment based peptide vaccines from trichinella spiralis. Drug Des. 2014;1:101.
50. Den Haan Het al. Application of modern drug discovery techniques in the context of diabetes mellitus and atherosclerosis. Drug Des. 2015;4:e125.
51. Gomase VS and Kale KV. Information of surface accessibility of the peptide fragments of coat protein from alfalfamosaic virus (amv) at the physicochemical and immunochemical levels. Drug Des. 2015;4:119.
52. Yuh-Jenn Wuet al. Evaluating the relative cost of a targeted design versus an untargeted design for randomized clinical trials. Drug Des. 2015;4:120.
53. Bule MHet al. Synthesis and in-vivo pharmacological evaluation of some novel 4(3h)-
54. quinazolinone derivatives as potential anti-malarial agents. Drug Des. 2015;4:121.
55. Soave Cet al. Repositioning an old antialcoholism drug: disulfiram as a selective, effective and economical anticancer agent. J Develop Drugs. 2016;5:e147.
56. Sreelakshmy Vet al. Green synthesis of silver nanoparticles from glycyrrhiza glabra root extract for the treatment of gastric ulcer. J Develop Drugs. 2016;5:152
57. Reure J, et al. Her2 Positive Metastatic Breast Cancer Patient without Any Sign of Recurrence 5 years after Cessation of Trastuzumab: A Case Report Clin Pharmacol Biopharm. 2015;4:136.
58. Morin C, et al. Late Onset Infections after Surgical Treatment of Spinal Deformities in Children. J Spine. 2015;4:262.
59. Bhat IH, et al. Clinical Profile and Outcome in Distal Gastrointestinal Tract Obstruction in Neonates with Special Emphasis on Role of Colostomy and its Complications. Anat Physiol. 2016;6:222.
60. Abbas A. Screening and Prevention of Transmission of HIV-1 in Neonates Born to Mothers with HIV. Int J Pub Health Safe. 2016; 1:103.
61. Saito M, et al. High Dose Octreotide for the Treatment of Chylothorax in Three Neonates. J Neonatal Biol. 2016;5:218.
62. Ogbalu OK, et al. A New Trend of Omphalitis Complicated with Myiasis in Neonates of the Niger Delta, Nigeria. Epidemiology Sunnyvale. 2016;6:231.
63. Kurt A, et al. Exposure to Environmental Tobacco Smoke during Pregnancy Restrain the Antioxidant Response of their Neonates. J Neonatal Biol. 2016;5:210.
64. Kondo M.NPC-11 Phase III Trial Concerning Apnea of Prematurity in Japanese Neonates: A Study of Safety, Efficacy and Pharmacokinetics. Pharm Anal Acta. 2016;7:458.
65. Garcia AJ and Smith JM Bile Duct Brushings in a Jaundiced Woman. 2015.
66. Alvarez AM, et al. Non-communicating Mucinous Biliary Cystadenoma as a Rare Cause of Jaundice. J CytolHistol. 2015; 6:369.
67. Morin C, et al. Late Onset Infections after Surgical Treatment of Spinal Deformities in Children. J Spine. 2015; 4:262.
68. Lopes CM. Therapeutics delivery: innovations technology approaches. Lopes, Drug Des. 2014;3:e123.
69. Chow SC. On assessment of analytical similarity in biosimilar studies. Drug Des. 2014;3:e124.
70. Lu Qet al. On two-stage adaptive seamless design with count data from different study durations under weibull distribution. Drug Des. 2014;3:114.
71. Sherkhane AS and Gomase VS. Identification of binding affinity of tap peptides for development of fragment based vaccine from long neurotoxin 2 [N. naja]. Drug Des. 2014;3:115.
72. Toshihiko T. Multifunctionality of drug’s pharmacophores within an organism. Drug Des. 2014;3:116.
73. Bielecka AM and Obuchowicz E. Chronic physiological hypoxia and high glucoseconcentration promote resistance of t98g glioblastoma cell line to temozolomide. Drug Des. 2014;3:117.
74. Stoicescu M and Bungau S. Contraceptive pills consumption risk factor of the breast cancer original case report. Drug Des. 2014;3:118.
75. Lopes CM and Soares C. Transdermal drug delivery systems activated by physical stimuli: techniques and applications. Drug Des. 2015;4:e129.
76. El-Bastawissy EA and Elhasab MA. Molecular docking and molecular dynamic simulation: insight into the difference in binding of hcv ns3/4a macrocclic inhibitors to genotypes 1b and 4a. Drug Des. 2015;4:124.
77. Fang J. Reliability of machine learning based algorithms for designing protein drugs with enhanced stability. Drug Des. 2015;4:e130.
78. Tutar L et al.Structure Based Drug Design for Heat Shock Proteins. Drug Des2016;5:e130.
79. Ceron-Carrasco JPet al. Application of computational drug discovery techniques for designing new drugs against zika virus. Drug Des. 2016;5:e131.
80. Gopi Set al. Effective drug delivery system of biopolymers based on nanomaterials and hydrogels -a review. Drug Des. 2016;5:129.
81. Ogikubo Y and AkitsuT. Enhancing medical or biological functions of laccase by cyanide-bridged cu(ii)-fe(iii) bimetallic complexes madiators. Drug Des. 2016;5:130.
82. Kahouli Iet al. Characterization of L. reuteriNCIMB 701359 probiotic features for potential use as a colorectal
83. cancer biotherapeutic by identifying fatty acid profile and anti-proliferative action against colorectal cancer cells. Drug Des. 2016;5:131.
84. Chow SC and Song F. Reproducible clinical research. Drug Des. 2016;5:132.
85. Damodar Ret al. Formulation and evaluation of fast dissolving tablets of diclofenac sodium by novel hole technology. J Mol Pharm Org Process Res. 2014;2:116.
86. Yuh-Jenn Wuet al. Evaluating the relative cost of a targeted design versus an untargeted design for randomized clinical trials. Drug Des. 2015;4:120.
87. Bule MHet al. Synthesis and in-vivo pharmacological evaluation of some novel 4(3h)-quinazolinone derivatives as potential anti-malarial agents. Drug Des. 2015;4:121.
88. Soave Cet al. Repositioning an old antialcoholism drug: disulfiram as a selective, effective and economical anticancer agent. J Develop Drugs. 2016;5:e147.
89. Sreelakshmy Vet al. Green synthesis of silver nanoparticles from glycyrrhiza glabra root extract for the treatment of gastric ulcer. J Develop Drugs. 2016;5:152
90. Reure J, et al. Her2 Positive Metastatic Breast Cancer Patient without Any Sign of Recurrence 5 years after Cessation of Trastuzumab: A Case Report Clin Pharmacol Biopharm. 2015;4:136.
91. Morin C, et al. Late Onset Infections after Surgical Treatment of Spinal Deformities in Children. J Spine. 2015;4:262.
92. Bhat IH, et al. Clinical Profile and Outcome in Distal Gastrointestinal Tract Obstruction in Neonates with Special Emphasis on Role of Colostomy and its Complications. Anat Physiol. 2016;6:222.
93. Abbas A. Screening and Prevention of Transmission of HIV-1 in Neonates Born to Mothers with HIV. Int J Pub Health Safe. 2016;1:103.
94. Saito M, et al. High Dose Octreotide for the Treatment of Chylothorax in Three Neonates. J Neonatal Biol. 2016;5:218.
95. Ogbalu OK, et al. A New Trend of Omphalitis Complicated with Myiasis in Neonates of the Niger Delta, Nigeria. Epidemiology Sunnyvale. 2016;6:231.
96. Kurt A, et al. Exposure to Environmental Tobacco Smoke during Pregnancy Restrain the Antioxidant Response of their Neonates. J Neonatal Biol. 2016;5:210.
97. Alvarez AM, et al. Non-communicating Mucinous Biliary Cystadenoma as a Rare Cause of Jaundice. J CytolHistol. 2015;6:369.
98. Vaz RJ. Fingerprints, facial recognition and cancer. Drug Des. 2016;5:133.
99. Toshihiko T. Multifunctionality of drug’s pharmacophores within an organism. Drug Des. 2014;3:116.
100. Bielecka AM and Obuchowicz E. Chronic physiological hypoxia and high glucoseconcentration promote resistance of t98g glioblastoma cell line to temozolomide. Drug Des. 2014;3:117.